

# Working memory in children with attention-deficit/hyperactivity disorder (ADHD): the impact of methylphenidate (MPH)

<b>Submission date</b> 23/01/2004	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 23/01/2004	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 12/12/2019	<b>Condition category</b> Mental and Behavioural Disorders	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr Kim Cornish

### Contact details

Developmental Psychiatry  
Division of Psychiatry  
E Floor, South Block  
South Block  
Queens Medical Centre  
Nottingham  
United Kingdom  
NG7 2UH  
+44 (0)115 924 9924  
[kim.cornish@mcgill.ca](mailto:kim.cornish@mcgill.ca)

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

## Secondary identifying numbers

RBP 98X24

# Study information

## Scientific Title

Working memory in children with attention-deficit/hyperactivity disorder (ADHD): the impact of methylphenidate (MPH)

## Study objectives

To address the following questions: What are the effects of methylphenidate on working memory in children with ADHD? Is there evidence for differential effects of MPH on working memory function? What is the relationship between the effects of MPH on working memory, behavioural inhibition, non-executive memory performance and hyperactive/impulsive behaviour?

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

Treatment

## Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

## Health condition(s) or problem(s) studied

Behavioural disorders

## Interventions

1. Methylphenidate (MPH) treatment
2. No methylphenidate treatment

## Intervention Type

Other

## **Phase**

Not Specified

## **Primary outcome measure**

1. Information about effects of MPH on cognitive function (including the possibility of cognitive toxicity) in children with ADHD
2. Greater understanding of the underlying cognitive processes in ADHD  
This knowledge of underlying mechanisms will lead to improved specificity of early detection, diagnosis and treatment of ADHD
3. Identification of potential cognitive deficits in ADHD. If persisting cognitive deficits are identified. These will be rational targets for supplementary treatment interventions
4. Suggestion of tests to monitor the effects of MPH on cognitive function which could be developed for use in everyday clinical practice.

## **Secondary outcome measures**

Not provided at time of registration

## **Overall study start date**

01/09/1998

## **Completion date**

29/02/2000

# **Eligibility**

## **Key inclusion criteria**

60 boys aged between 7-12 years, receiving MPH, with a diagnosis of Hyperkinetic disorder or the equivalent ADHD combined sub-type, will be recruited from out-patient psychiatric clinics in the Trent region.

## **Participant type(s)**

Patient

## **Age group**

Child

## **Lower age limit**

7 Years

## **Upper age limit**

12 Years

## **Sex**

Male

## **Target number of participants**

60

**Key exclusion criteria**

Does not match inclusion criteria

**Date of first enrolment**

01/09/1998

**Date of final enrolment**

29/02/2000

**Locations****Countries of recruitment**

England

United Kingdom

**Study participating centre****Queens Medical Centre**

Nottingham

United Kingdom

NG7 2UH

**Sponsor information****Organisation**

NHS R&D Regional Programme Register - Department of Health (UK)

**Sponsor details**

The Department of Health

Richmond House

79 Whitehall

London

United Kingdom

SW1A 2NL

+44 (0)20 7307 2622

dhmail@doh.gsi.org.uk

**Sponsor type**

Government

**Website**

<http://www.doh.gov.uk>

# **Funder(s)**

## **Funder type**

Hospital/treatment centre

## **Funder Name**

NHS Executive Trent (UK)

# **Results and Publications**

## **Publication and dissemination plan**

Not provided at time of registration

## **Intention to publish date**

## **Individual participant data (IPD) sharing plan**

## **IPD sharing plan summary**

Not provided at time of registration